In this edition, a phase 3 trial of a regimen for small cell lung cancer misses its co-primary endpoint; obesity and pulmonary function may identify the need for home oxygen after lung cancer surgery; a study finds that lung cancer screening is less common among those most likely to benefit from it; and more.
Read the full coverage here:
Phase 3 trial of regimen for small cell lung cancer misses co-primary endpoint
Obesity, pulmonary function may identify need for home oxygen after lung cancer surgery
Lung cancer screening less common among those most likely to benefit from it
FDA rejects sintilimab with chemotherapy for non-small cell lung cancer
Blood-based microRNA signature may predict survival in immunotherapy-treated NSCLC
References:
Nicastri DG, et al. Ann Am Thorac Soc. 2022;doi:10.1513/AnnalsATS.202103-231OC.
Rustagi AS, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.5318.
Rajakumar T, et al. npj Precis Oncol. 2022;doi:10.1038/s41698-022-00262-y.
